Diabetes Care, Vol 20, Issue 12 1827-1832, Copyright © 1997 by American Diabetes Association

ARTICLES

Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group

F Holleman, H Schmitt, R Rottiers, A Rees, S Symanowski and JH Anderson
Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands. fhollema@worldonline.nl

OBJECTIVE: Several studies have suggested that use of the short-acting insulin analog, insulin lispro, in multiple injection therapy may reduce the risk of hypoglycemia in comparison with regular insulin. This effect might be more pronounced in well-controlled patients, since intensive treatment of IDDM increases the rate of severe hypoglycemic events. This study evaluated the effects of insulin lispro on glycemic control and hypoglycemia rates in well-controlled IDDM patients. RESEARCH DESIGN AND METHODS: This was an open, randomized, 6-month crossover study of 199 IDDM patients. Glycemic control was evaluated by HbA1c, home blood glucose measurements, and rate and timing of hypoglycemic events. At the end of the study, patients completed an evaluation form regarding therapy-related quality of life. RESULTS: HbA1c remained constant at approximately 7.3% throughout the study. Meal-related glucose excursions were significantly lower with insulin lispro compared with regular insulin (mean -0.8 +/- 1.7 vs. 1.1 +/- 1.6 mmol/l, P < 0.001), as was the within-day variability (M value 27.7 +/- 19.7 vs. 30.2 +/- 23.1, P = 0.007). The incidence of severe hypoglycemic events (58 vs. 36, P = 0.037) including coma (16 vs. 3, P = 0.004) was significantly lower with insulin lispro than with regular insulin. Patients felt that insulin lispro increased flexibility and freedom of lifestyle. CONCLUSIONS: In well-controlled IDDM patients, insulin lispro is associated with a lower risk of severe hypoglycemia and coma.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				E. A.M. Gale, S. D. Beattie, J. Hu, V. Koivisto, and M. H. Tan Recruitment to a Clinical Trial Improves Glycemic Control in Patients With Diabetes Diabetes Care, December 1, 2007; 30(12): 2989 - 2992. [Abstract] [Full Text] [PDF]

				P. Hollander Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes Diabetes Spectr, July 1, 2007; 20(3): 159 - 165. [Abstract] [Full Text] [PDF]

				J. Plank, A. Siebenhofer, A. Berghold, K. Jeitler, K. Horvath, P. Mrak, and T. R. Pieber Systematic Review and Meta-analysis of Short-Acting Insulin Analogues in Patients With Diabetes Mellitus Arch Intern Med, June 27, 2005; 165(12): 1337 - 1344. [Abstract] [Full Text] [PDF]

				K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				A. M.E. Stades, J. B.L. Hoekstra, I. van den Tweel, D. W. Erkelens, and F. Holleman Additional Lunchtime Basal Insulin During Insulin Lispro Intensive Therapy in a Randomized, Multicenter, Crossover Study in Adults : A real-life design Diabetes Care, April 1, 2002; 25(4): 712 - 717. [Abstract] [Full Text] [PDF]

				I. M. Evers, E. W.M.T. ter Braak, H. W. de Valk, B. van der Schoot, N. Janssen, and G. H.A. Visser Risk Indicators Predictive for Severe Hypoglycemia During the First Trimester of Type 1 Diabetic Pregnancy Diabetes Care, March 1, 2002; 25(3): 554 - 559. [Abstract] [Full Text] [PDF]

				E. Tsui, A. Barnie, S. Ross, R. Parkes, and B. Zinman Intensive Insulin Therapy With Insulin Lispro: A randomized trial of continuous subcutaneous insulin infusion versus multiple daily insulin injection Diabetes Care, October 1, 2001; 24(10): 1722 - 1727. [Abstract] [Full Text] [PDF]

				A. Bhattacharyya, S. Brown, S. Hughes, and P.A. Vice Insulin lispro and regular insulin in pregnancy QJM, May 1, 2001; 94(5): 255 - 260. [Abstract] [Full Text] [PDF]

				H. P. Chase, T. Lockspeiser, B. Peery, M. Shepherd, T. MacKenzie, J. Anderson, and S. K. Garg The Impact of the Diabetes Control and Complications Trial and Humalog Insulin on Glycohemoglobin Levels and Severe Hypoglycemia in Type 1 Diabetes Diabetes Care, March 1, 2001; 24(3): 430 - 434. [Abstract] [Full Text]

				J. H. Silverstein and A. L. Rosenbloom New Developments in Type 1 (Insulin-Dependent) Diabetes Clinical Pediatrics, May 1, 2000; 39(5): 257 - 266. [Abstract] [PDF]

				M. Gray, E. A. Boland, and W. V. Tamborlane Use of Lispro Insulin and Quality of Life in Adolescents on Intensive Therapy The Diabetes Educator, November 1, 1999; 25(6): 934 - 941. [Abstract] [PDF]

				B. Guerci, L. Meyer, A. Sallé, A. Charrié, B. Dousset, O. Ziegler, and P. Drouin Comparison of Metabolic Deterioration between Insulin Analog and Regular Insulin after a 5-Hour Interruption of a Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2673 - 2678. [Abstract] [Full Text]

				INSULIN LISPRO REDUCES SEVERE HYPOGLYCEMIA Journal Watch (General), December 19, 1997; 1997(1219): 3 - 3. [Full Text]